- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Joslin Study Finds Similar Benefits of Gastric Band and a Dietary Program
The study, called the the SLIMM-T2D (Surgery or Lifestyle with Intensive Medical Management in Treatment of Type 2 Diabetes) trial, was published in the Journal of Clinical Endocrinology & Metabolism and observed similar improvements in blood sugar control a year after gastric band surgery or being on a group-based weight management program.
Weight loss is never easy, but it's important for overweight people with type 2 diabetes seeking to control their blood sugar levels and optimize their health. A small clinical trial among such patients led by Joslin Diabetes Center and Brigham and Women's Hospital researchers now has shown that 2 approaches—adjustable gastric band surgery and an intensive group-based medical diabetes and weight management program—achieved similar improvements in controlling blood sugar levels after 1 year.
"We can anticipate long-term health benefits from both of these approaches, but they do require some investment of time and energy by the patient," says trial leader Allison Goldfine, MD, head of Joslin's Section of Clinical Research and an associate professor of Medicine at Harvard Medical School.
Reported in the Journal of Clinical Endocrinology & Metabolism, the SLIMM-T2D (Surgery or Lifestyle with Intensive Medical Management in Treatment of Type 2 Diabetes) trial enlisted 45 volunteers who had long-duration type 2 diabetes, struggled to manage their diabetes and had a body mass index of 30 or higher.
Link to the complete report on ScienceDaily:
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinerof cream.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
